News for INmune Bio, Inc. (INMB)

Shares of Calix, Inc. CALX rose sharply in today's pre-market trading as the company reported better-than-expected first-quarter financial results and issued st...

Net Loss: Approximately $42.1 million for the year ended December 31, 2024, compared to approximately $30 million for 2023.Research and Development Expenses: A

Mar 27, 2025 / 08:30PM GMTOperator Greetings and welcome to the Immune BIO's 2024 4th quarter and full year earnings call. (Operator Instructions) As a reminder

Discover key insights from INmune Bio's Q4 2024 earnings: Alzheimer's trial data due in June, oncology advancements, and groundbreaking RDEB treatments.

INmune Bio, Inc. (NASDAQ:INMB) Q4 2024 Results Conference Call March 27, 2025 4:30 PM ETCompany ParticipantsDavid Moss - CFORaymond Tesi - CEO &...

Company to Host Conference Call Today, March 27, at 4:30pm ET BOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. ( INMB) (the ”œCompany”

Revenue: Reported revenue of $0.01 million, meeting the estimated revenue target.Earnings Per Share (EPS): Reported EPS of -$0.53, meeting the estimated EPS.Ph

Boca Raton, Florida, March 24, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. ( INMB) (the ”œCompany”), a clinical-stage inflammation and immunology company, to

Transaction Overview On March 12, 2025, Dauntless Investment Group, LLC (Trades, Portfolio) made a strategic move by acquiring 1,999,380 shares of OKYO Pharma L

INmune Bio's high-upside potential with CORDStrom for RDEB and XPro for Alzheimer's, offering up to 144.8x returns. Click here to read why INMB is a Strong Buy.

On February 26, 2025, Dauntless Investment Group, LLC (Trades, Portfolio) made a strategic move by acquiring 108,224 shares of AEON Biopharma Inc. The transacti

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where INmune Bio, Inc.

**media[538627]**

Medical review of Phase 1 cohorts demonstrated no safety issuesData to be presented at the 10th Annual Innate Killer Summit, March 3-5 BOCA RATON, Fla, Feb. 1

**media[536560]**

The Company reports results of a double-blinded, randomized, placebo-controlled study, known as ”œMissionEB,” investigating CORDStrom for treatment of RDEB i

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where INmune Bio Inc (NASDAQ:INMB) stands against the...

**media[526227]**

Significant Transaction by Praetorian PR LLC (Trades, Portfolio) On January 15, 2025, Praetorian PR LLC (Trades, Portfolio) executed a noteworthy transaction in